Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Medimaging Integrated Solution Inc. (6796.TW)
Hsinchu City, TW
Medimaging Integrated Solution Inc. specializes in delivering advanced digital and mobile diagnostic technology. The company engineers and produces a variety of digital handheld diagnostic scopes, alongside their essential auxiliary equipment. A key product line is the Horus scope system, which encompasses optical coherence tomography (OCT) capabilities, integrated control units, specialized software, and a full suite of accessories. Beyond hardware, Medimaging leverages artificial intelligence for screening applications, notably in detecting diabetic retinopathy, managing wound care, and supporting general medical diagnosis. They also provide comprehensive endoscopy solutions, utilizing advanced micro camera modules to ensure superior visualization and facilitate patient-focused care. These high-performance micro camera modules are also available as standalone components. Established in 2010, Medimaging Integrated Solution Inc. maintains its headquarters in Hsinchu City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.74% | -4.71% | -6.06% | -20.97% | -26.78% | -29.19% | -2.43% | -23.93% | +54.86% | +14.15% | +14.15% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Devices: +11.2%+22.7% ★ Q1'26: +10.3% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+37.5% ★ Q1'26: -980.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-8.7% Q1'26: -4.2% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+2.7% Q1'26: -13.2% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+1.2% Q1'26: -8.4% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-0.2% ★ Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×9.05× Q1'26: -8.68× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 3/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 27.8K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chu-Ming Cheng | Chief Executive Officer, Chairman & President | 4M | male |
| Chih-Lu Hsu | Vice President | 3M | male |
| Hui-Yu Ko | Vice President | 3M | female |
| Ching Yi Fan | Deputy Director of the Finance & Accounting | — | — |
| Shih-Ting Huang | Chief Accounting Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6796.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
